A. Zaanan

W. Cacheux, O. Bouché, D. Tougeron, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers

J. Sabourin, R. Guimbaud, M. Auriault, 2022, International journal of molecular sciences.

Prognostic factors of Colorectal Cancer patients with Brain Metastases.

A. Lièvre, D. Tougeron, J. Bennouna, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis

A. Schreurs, C. Desbois-Mouthon, C. Miquel, 2014, Oncogene.

Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer

J. Taieb, S. Pernot, A. Zaanan, 2016 .

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E‐mutated and microsatellite unstable metastatic colorectal cancer patient: A case report

S. Garinet, J. Taieb, A. Zaanan, 2021, Genes, chromosomes & cancer.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Chemosensitivity in ovarian metastases from gastric cancer: a case series.

P. Rougier, J. Taieb, A. Berger, 2013, Clinics and research in hepatology and gastroenterology.

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries

M. Pocard, J. Taieb, A. Zaanan, 2020, Pleura and peritoneum.

Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk

P. Laurent-Puig, J. Duffour, J. Saurin, 2015, European Journal of Human Genetics.

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients

M. Pocard, G. Piessen, C. Lombard-Bohas, 2020, International journal of cancer.

Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study

Z. Ge, Yun-jie Gao, Qi-Wen Wang, 2020, EBioMedicine.

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

M. Ziol, M. Ronot, V. Paradis, 2022, Liver Cancer.

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study

T. Matysiak-Budnik, D. Tougeron, J. Bennouna, 2017, British Journal of Cancer.

Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer.

F. Sinicrope, J. Bachet, T. André, 2014, Current colorectal cancer reports.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

P. Laurent-Puig, P. Rougier, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Brain metastases from pancreatic adenocarcinoma

A. Lièvre, J. Taïeb, B. Landi, 2009, BMJ Case Reports.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019 .

Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.

F. Caroli-Bosc, G. Piessen, M. Perrier, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

533PA large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability

J. Taieb, R. Coriat, T. André, 2017 .

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.

G. Piessen, F. Bibeau, F. Ghiringhelli, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Efficacy of anti-EGFR in MSI metastatic colorectal cancer depending on sporadic or familial origin.

D. Vernerey, J. Taieb, M. Svrcek, 2020, Journal of the National Cancer Institute.

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

[Clinical and molecular consequences of microsatellite instability in human cancers].

H. Zouali, A. Duval, R. Hamelin, 2008, Bulletin du cancer.

Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens

P. Rougier, J. Taieb, O. Pellerin, 2015 .

Localized Small Bowel Adenocarcinoma Management: Evidence Summary

A. Zaanan, M. El Amrani, A. Turpin, 2022, Cancers.

Effectiveness of a dedicated small bowel neoplasia screening program by capsule endoscopy in Lynch syndrome: 5 years results from a tertiary care center

P. Laurent-Puig, C. Cuénod, C. Cellier, 2020, Therapeutic advances in gastroenterology.

Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.

M. Boubaya, V. Boige, R. Coriat, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Small bowel polyp resection using device-assisted enteroscopy in Peutz-Jeghers Syndrome: Results of a specialised tertiary care centre

P. Laurent-Puig, C. Cuénod, A. Berger, 2020, United European gastroenterology journal.

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

M. Ychou, P. Rougier, T. Mazard, 2014, Gastric Cancer.

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

I. Sobhani, P. Laurent-Puig, F. Bonnetain, 2013, British Journal of Cancer.

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

L. Kong, L. Shen, Y. Shu, 2022, BMJ.

Drastic decrease of urgent endoscopies outside regular working hours during the Covid-19 pandemic in the paris area

A. Amiot, I. Sobhani, M. Rudler, 2020, Clinics and Research in Hepatology and Gastroenterology.

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2020, Clinics and research in hepatology and gastroenterology.

A Case of 5‐FU‐Related Severe Toxicity Associated with the p.Y186C DPYD Variant

M. Loriot, J. Taieb, A. Zaanan, 2014, Clinical pharmacology and therapeutics.

Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2019, Journal of Clinical Oncology.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer

P. Laurent-Puig, C. Montagut, M. Peeters, 2019, Drugs.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells

Aziz Zaanan, Shengbing Huang, F. Sinicrope, 2014, Molecular Cancer Research.

Colorectal Cancer: Why Does Side Matter?

J. Taieb, S. Pernot, A. Zaanan, 2018, Drugs.

Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives

J. Taïeb, S. Pernot, A. Zaanan, 2020, Drugs.

Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications

J. Fléjou, F. Praz, A. Zaanan, 2011, Cellular Oncology.

Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer

F. Sinicrope, H. Kawakami, A. Zaanan, 2015, Current Treatment Options in Oncology.

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment.

P. Laurent-Puig, N. Carrère, M. Svrcek, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

I. Sobhani, J. Taïeb, F. Bonnetain, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.

P. Laurent-Puig, J. Taieb, V. Taly, 2020, Cancer treatment reviews.

Exploring the best treatment options for BRAF-mutant metastatic colon cancer

J. Taieb, A. Zaanan, A. Lapeyre-Prost, 2019, British Journal of Cancer.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy in advanced gastric cancer, is it the future?

N. Chaput, C. Coutzac, S. Pernot, 2019, Critical reviews in oncology/hematology.

Biomarkers for Immunotherapy in Gastrointestinal Cancers

J. Taieb, A. Zaanan, J. Palle, 2021, Cancer Immunotherapy.

Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2015 .

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.

P. Validire, B. Gayet, A. Duval, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives

P. Laurent-Puig, S. Garinet, J. Taieb, 2021, Cancers.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

I. Sobhani, G. Chatellier, P. Laurent-Puig, 2016, Clinical chemistry.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

A. Lièvre, W. Cacheux, R. Guimbaud, 2019, The oncologist.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

P. Laurent-Puig, J. Tabernero, C. Lepage, 2016, JAMA oncology.

Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAFV600E Mutations in Patients with Lymph-Node-Positive Colon Cancer

F. Sinicrope, J. Bachet, T. André, 2014, Current Colorectal Cancer Reports.

Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

J. Taïeb, F. Bonnetain, D. Malka, 2011, Cancer.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

J. Taieb, T. Aparicio, M. Gauthier, 2014, BMC Cancer.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

M. Pocard, R. Benamouzig, O. Bouché, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.

D. Aust, P. Laurent-Puig, H. Blons, 2014, European journal of cancer.

[Microsatellite instability and cancer: from genomic instability to personalized medicine].

A. Duval, J. Lefèvre, A. Collura, 2019, Medecine sciences : M/S.

Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects.

E. Tartour, J. Taieb, S. Pernot, 2014, Clinics and research in hepatology and gastroenterology.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

J. Taïeb, V. Boige, M. Hebbar, 2013, Journal of hepatology.

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort

A. Lièvre, M. Pocard, G. Piessen, 2020, International journal of cancer.

Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives

M. Overman, E. Moati, A. Zaanan, 2022, Cancers.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Frédéric Ginot, Aziz Zaanan, Aurélien Bancaud, 2018, Analytical chemistry.

Impact of an optimized colonoscopic screening program for patients with Lynch syndrome: 6-year results of a specialized French network

G. Chatellier, C. Cellier, G. Rahmi, 2018, Therapeutic advances in gastroenterology.

Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer

Julien Taieb, Aziz Zaanan, J. Taieb, 2014, Nutrition and cancer.

Should mismatch repair status be determined in all stage II and III colon cancer patients

J. Taieb, A. Zaanan, 2014 .

Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy

P. Laurent-Puig, J. Taieb, O. Dubreuil, 2013 .

Small Bowel Adenocarcinoma.

T. Aparicio, T. Evans, A. Zaanan, 2016, Gastroenterology clinics of North America.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

J. Taïeb, F. Fein, F. Bonnetain, 2014, European journal of cancer.

Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.

C. Tournigand, O. Hentic, A. de Gramont, 2015, Bulletin du cancer.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

F. Fein, F. Bonnetain, J. Taieb, 2016, Quality of Life Research.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism*

F. Sinicrope, K. Khazaie, Shengbing Huang, 2015, The Journal of Biological Chemistry.

Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.

E. Vasile, A. Lièvre, W. Cacheux, 2019, European journal of cancer.

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study

J. Taieb, J. Bachet, K. Le Malicot, 2018, British Journal of Cancer.

Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

A. Santoro, M. Alsina, M. Tejani, 2019, Journal of Clinical Oncology.

Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays

P. Laurent-Puig, H. Blons, J. Taïeb, 2021, Frontiers in Oncology.

Implications of mismatch repair-deficient status on management of early stage colorectal cancer.

F. Sinicrope, H. Kawakami, A. Zaanan, 2015, Journal of gastrointestinal oncology.

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

A. Lièvre, W. Cacheux, J. Taieb, 2015, Cancer.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

P. Laurent-Puig, N. Siauve, H. Blons, 2017, Clinical Cancer Research.

Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma

Tsung-Teh Wu, N. Foster, F. Sinicrope, 2015, International journal of cancer.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

P. Validire, B. Gayet, H. Blons, 2019, Cellular Oncology.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, H. Sokol, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study

G. Prager, R. Guimbaud, L. Mineur, 2023, Gastric Cancer.

Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials.

D. Sargent, P. Laurent-Puig, R. Goldberg, 2020, JCO precision oncology.

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

A. Lièvre, P. Hammel, J. Taieb, 2022, International journal of cancer.

Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin

P. Validire, B. Gayet, A. Duval, 2008 .

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

E. Tartour, F. Ghiringhelli, J. Taieb, 2021, Cancers.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

P. Laurent-Puig, H. Blons, J. Taieb, 2018, Clinics and research in hepatology and gastroenterology.

Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

J. Taieb, B. Landi, J. Bachet, 2011, Clinics and research in hepatology and gastroenterology.

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

P. Validire, B. Gayet, H. Blons, 2019, Cellular Oncology.

Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

P. Laurent-Puig, R. Goldberg, T. Smyrk, 2020, European Journal of Cancer.

Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study

J. Taieb, D. Tougeron, P. Artru, 2018, Targeted Oncology.

Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.

M. Loriot, N. Pallet, V. Boige, 2022, European journal of cancer.

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

M. Loriot, H. Blons, N. Pallet, 2020, British Journal of Cancer.

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

M. Loriot, H. Blons, N. Pallet, 2020, British Journal of Cancer.

Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives.

M. Loriot, N. Pallet, J. Taieb, 2023, Clinica chimica acta; international journal of clinical chemistry.

Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

M. Ducreux, B. Buecher, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.

S. Garinet, J. Taieb, A. Zaanan, 2021, European journal of cancer.

Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey.

P. Laurent-Puig, F. Puglisi, C. Lepage, 2021, Clinics and research in hepatology and gastroenterology.

Adjuvant FOLFOX +/− cetuximab in full RAS and BRAF wildtype stage III colon cancer patients

P. Laurent-Puig, E. Van Cutsem, J. Tabernero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

C. Tournigand, H. Sokol, A. Duval, 2020 .

ERBB3-Activating Mutations in Small Bowel Adenocarcinomas.

S. Vacher, I. Bièche, P. Laurent-Puig, 2018, JCO precision oncology.

Comparison of three lymph node staging schemes for predicting the outcome in patients with small bowel adenocarcinoma: A population-based cohort and international multicentre cohort study

Qing-Wei Zhang, T. Aparicio, Sunkuan Hu, 2019, EBioMedicine.

Prognostic value of Lynch syndrome, BRAFV600E , and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts

C. Punt, M. Koopman, D. Tougeron, 2023, Cancer medicine.

Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study.

S. Doat, J. Bachet, D. Tougeron, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection

J. Taieb, A. Zaanan, L. Rebibo, 2023, Langenbeck's Archives of Surgery.

Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study.

D. Vernerey, F. Bonnetain, J. Taieb, 2014 .

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

J. Taieb, A. Zaanan, 2018, Bulletin du cancer.

A large multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancers with microsatellite instability.

J. Taieb, R. Coriat, D. Tougeron, 2017 .

[Small bowel adenocarcinoma].

N. Carrère, T. Aparicio, A. Zaanan, 2010, Gastroenterologie clinique et biologique.

[Immunotherapy in advanced gastric cancer].

A. Zaanan, A. Zaanan, 2022, Bulletin du cancer.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

[Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]

J. Taieb, A. Zaanan, J. Taieb, 2019, Bulletin du cancer.

Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data

Moreno Ursino, Sarah Zohar, Bruno Landi, 2019, Statistical methods in medical research.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

J. Taïeb, V. Boige, M. Hebbar, 2013, Journal of hepatology.

Clinics and research in hepatology and gastroenterology

ScienceDirect, M. Rudler, X. Causse, 2011 .

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.

D. Botsen, S. Ammari, P. Decazes, 2024, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Pembrolizumab+chemotherapy as first-line treatment in patients with HER negative advanced oesogastric adenocarcinoma].

A. Zaanan, M. Duval, 2024, Bulletin du cancer.

Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)

P. Laurent-Puig, N. Siauve, H. Blons, 2017, Clinical Cancer Research.

Treatment of gastric adenocarcinoma: A rapidly evolving landscape.

J. Bennouna, E. Samalin, A. Zaanan, 2023, European journal of cancer.

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases

O. Glehen, A. Zaanan, M. Karoui, 2022, Annals of Surgical Oncology.

Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment.

P. Laurent-Puig, N. Carrère, M. Svrcek, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Small bowel adenocarcinoma].

N. Carrère, A. Zaanan, P. Afchain, 2010, Gastroenterologie clinique et biologique.